Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7086632 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL13395477 | 0.84 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL829647 | 0.84 | GABRA1 (0.64) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL385458 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL2351650 | 0.82 | GABRA1 (0.60) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL830378 | 0.82 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL1259124 | 0.81 | KDM4E (0.61) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL830073 | 0.81 | KDM4E (0.54) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL13336465 | 0.80 | GAA (0.66) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL333983 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012059568-A1 | NOVEL WATER-SOLUBLE INDOLOBENZAZEPINE MOLECULES DEMONSTRATING ANTIMITOTIC, ANTIVASCULAR, AND ANTITUMOR ACTIVITIES IN VIVO | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-05-10 | — | — | WO | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | ALDH1A1 2482/4885KDM4E 2071/4885HPGD 3175/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | ALDH1A1 1792/4885KDM4E 1061/4885HPGD 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.